Loading clinical trials...
Loading clinical trials...
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Conditions
Interventions
GSK2798745
Locations
11
United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Lake Worth, Florida, United States
GSK Investigational Site
Winter Haven, Florida, United States
GSK Investigational Site
Shirley, New York, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
McAllen, Texas, United States
Start Date
September 7, 2020
Primary Completion Date
April 11, 2022
Completion Date
April 11, 2022
Last Updated
November 8, 2024
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT05976139
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions